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Precis: Regorafenib has been shown to confer a survival benefit as a second line systemic treatment for 
advanced hepatocellular carcinoma. This study examines the cost-effectiveness of regorafenib in this 
setting.  
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Abstract 
Background: Regorafenib, a multikinase inhibitor, has been shown to prolong survival by 2.8 months as 
a 2nd line agent in patients with hepatocellular carcinoma (HCC) who progress on sorafenib therapy. We 
aimed to examine the cost-effectiveness of regorafenib for the treatment of HCC.  
Methods: We constructed a Markov simulation model of patients with unresectable HCC and Child Pugh 
A cirrhosis treated with regorafenib versus best supportive care. Model inputs for regorafenib 
effectiveness and rates of adverse events in HCC patients were based on published clinical trial data and 
literature review. We calculated quality adjusted life years (QALYs) and the incremental cost-
effectiveness ratio (ICER) of regorafenib therapy. We conducted one-way sensitivity analyses on all 
model parameters and Monte-Carlo simulation varying model parameters simultaneously. We 
determined at which regorafenib cost threshold, cost-effectiveness would be achieved. 
Results: Regorafenib provided an increase of 0.18 QALYs at a cost of $47,112. The ICER for regorafenib 
compared to best supportive care was $224,362. In one-way sensitivity analyses, there were no 
scenarios in which regorafenib was cost effective.  In cost threshold analysis, regorafenib would need to 
be priced at or below $67 per pill to be cost-effective at an ICER of $100,000. 
Conclusion: Regorafenib is not cost-effective as a second-line agent in the treatment of HCC with a 
marginal increase in QALYs at a high cost. Lowering costs of regroafenib or improving selection of 
patients with maximal survival benefit would improve its value as a second-line treatment option for 
patients with HCC. 
Keywords: HCC, Markov, ICER, QALY, RESORCE 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is an increasingly incident malignancy in the United States 
associated with significant morbidity and mortality.1-3 Despite improvement over time, the majority of 
HCC patients continue to present at advanced stages, when curative treatment options are not possible 
and prognosis is poor.4, 5 In the most recent 10-year period assessed by SEER, primary liver cancer had 
the largest relative increase in mortality among all solid tumors.6  
Systemic therapy is the primary treatment modality for patients with advanced HCC, including 
those with portal vein invasion or extra-hepatic spread.7 Similarly, there is increasing recognition of 
systemic therapy’s role for patients who progress after treatment with locoregional therapy, such as 
transarterial chemoembolization (TACE). Sorafenib, an oral multikinase inhibitor, is the only FDA-
approved first-line therapy for patients with advanced HCC.8, 9 Sorafenib was approved in patients with 
unresectable HCC based on results from the Sorafenib Hepatocellular Carcinoma Assessment 
Randomized Protocol (SHARP) Trial, which showed patients treated with sorafenib experienced 
significantly prolonged time-to-radiologic progression (5.5 vs. 2.8 months, p<0.001 ) and improved 
overall survival (10.7 vs. 7.9 months p<0.001).10 Based on these data, sorafenib is the most commonly 
used systemic therapy in patients with advanced HCC, including expanded use in patients with Child 
Pugh B and even some patients Child Pugh C cirrhosis.9 Cost-effectiveness analyses have demonstrated 
that sorafenib is cost-effective in patients with Child Pugh A cirrhosis, including in elderly patients, 
although it is no longer cost-effective in patients with hepatic decompensation.8 
 Until recently, there have not been any approved alternate therapies for patients who 
experience tumor progression or severe adverse events on sorafenib. Several therapies appeared 
promising in phase II studies but failed to improve survival when evaluated in larger phase III studies.11-13 
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Regorafenib is also a multikinase inhibitor that has been previously approved for use in patients 
with metastatic colorectal cancer and advanced gastrointestinal stromal tumors.14, 15 The RESORCE trial, 
a double blind phase III randomized control trial recently evaluated the efficacy of regorafenib 
compared to best supportive care in patients who experienced progression on sorafenib.16 Patients who 
received regorafenib had a median survival of 10.6 months versus 7.8 months for placebo (p<0.001).   
 An analysis of the cost-effectiveness of regorafenib as a 3rd line agent in patients with metastatic 
colorectal cancer demonstrated that it is not cost-effective compared to placebo with an incremental 
cost-effectiveness ratio (ICER) of $900,000 per quality life year (QALY) gained in the base model, and the 
ICER did not reach $550,000 in any of the sensitivity analyses.17 The authors concluded the cost-
effectiveness of regorafenib should be improved with use of value-based pricing. With its new indication 
for HCC treatment, we aimed to examine the cost-effectiveness of regorafenib as a second line agent in 
the treatment of advanced HCC.  
 
METHODS 
We constructed a Markov model of patients with advanced HCC in the setting of Child Pugh A 
cirrhosis and an Eastern Cooperative Oncology Group (ECOG) status of 0-1. Rates of disease progression 
for patients who progressed on sorafenib were based on results from the RESORCE Trial.16   This model 
tracked health states of patients as outlined in Figure 1. Patients treated with regorafenib continued on 
regorafenib until they experienced a grade 3-4 AE or radiographic HCC progression. Treated patients 
moved in weekly cycles to best supportive care or death. 
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The model was constructed using Microsoft Excel and tracked costs, QALYs, and the ICER 
comparing regorafenib versus best supportive care. Cost-effectiveness was calculated from a health 
system perspective.   
Model Inputs 
Progression Rates 
HCC progression rates in the model were calculated to match the median overall survival, median 
progression-free survival, and median time-to-progression observed in the RESORCE Trial.16  We 
assumed constant HCC progression rates over time. 
Adverse Events 
We included the impact of hypertension, hand-foot skin reaction, fatigue, and diarrhea, as these side-
effects were the most common clinically relevant grade 3 or 4 events in the trials of regorafenib for both 
HCC and colorectal cancers.14, 16  Rates of side effects were based on data from the RESORCE Trial.16 For 
management of grade 1-2 AEs, we modeled use of amlodipine 5 mg daily for hypertension, Eucerin 
cream for hand-foot skin reaction, and atropine / diphenoxylate and loperamide for diarrhea. Any 
occurrence of grade 3-4 AE resulted in regorafenib discontinuation with resultant resolution of the AE. 
Health Utilities 
We calculated health utilities based upon the quality of life data (EQ-5D, FACT-Hep) presented in the 
RESORCE trial.16 Although the study found a significant decrease in quality of life of patients treated with 
regorafenib, the quality of life decrement did not meet the threshold for a minimally important 
difference. RESORCE did not compare quality-of-life for patients with and without tumor progression, so 
we assumed quality-of-life was not different between progressed and non-progressed health states; 
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however, health utilities in patients with and without HCC progression were varied in sensitivity 
analyses. Health utilities were aggregated over weekly periods to calculate overall QALYs. 
Costs 
Both arms included costs of side effects and best supportive care, including general liver disease 
management.  Costs in the regorafenib arm included regorafenib medication costs as well as 
surveillance imaging associated with regorafenib monitoring.  Regorafenib costs were based on 
weighted average costs from the Red Book ($165 per 40mg)18, and adjusted based on mean daily dose 
observed in the RESORCE Trial (144mg per day).  Patients on regorafenib were modeled to receive three 
weeks on and one week off therapy, which is consistent with treatment schedule detailed in the 
RESORCE Trial. Discontinuation rates were modeled to match what was reported in the RESORCE Trial.  
In addition to drug costs, patients on regorafenib were assumed to have contrast-enhanced abdominal 
CT imaging at baseline and every 12 weeks until drug discontinuation or death. All costs were updated 
to 2016 dollars using the GDP deflator. Cost-effectiveness of regorafenib was defined as an ICER (i.e. 
difference in cost of two possible treatments divided by the difference in effect) of $100,000 compared 
to best supportive care.19-22 
Sensitivity Analysis 
We derived parameter ranges from the literature and performed one-way sensitivity analyses on all 
parameters as well as multi-way sensitivity analysis on key parameters of interest.  We also conducted a 
Monte-Carlo simulation of the model simultaneously drawing all parameter values and their ranges to 
evaluate overall uncertainty in results.  Using data from 10,000 iterations, we created cost-effectiveness 
acceptability curves representing the likelihood that regorafenib would be considered cost-effective at 
various levels of willingness-to-pay for health gains (QALYs). We modeled the potential impact of HCC 
progression on health utilities, given that HCC progression may negatively affect health related quality of 
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life. We also conducted a cost threshold analysis to determine at which pill cost regorafenib would 
become cost-effective. 
 
RESULTS 
Base Case 
The model inputs, including baseline values, ranges included in sensitivity analyses, costs and utilities 
and their sources are shown in Table 1. Our model’s progression-free and overall survival curves for 
both the regorafenib and placebo arms matched results of the RESORCE Trial. (Supplemental Figure 1A 
and 1B) The overall results of the base case analysis are shown in Table 2. Regorafenib provided an 
additional 0.18 QALYs (65 quality-adjusted days) compared to best supportive care. The cost incurred 
with regorafenib treatment was $47,112 vs $7,408 with best supportive care. Regorafenib was not cost-
effective with an ICER of $224,362 compared to best supportive care in our base case analysis. 
Sensitivity Analysis 
In one-way sensitivity analyses, the parameters with the most influence on ICER were related to HCC 
progression, particularly overall survival, and cost of regorafenib. (Figure 2) However, the ICER remained 
above $140,000 per QALY in each one-way sensitivity analysis. 
In the sensitivity analysis where we modeled decrease in health utility with HCC progression, we found 
the ICER rose to above $1,200,000 when the health utility associated with HCC progression was 
decreased to 0. If patients without HCC progression had improved health utility compared to the base 
case, the ICER decreased but did not fall below $210,000. (Supplemental Table 1). 
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In two-way sensitivity analyses, we varied the median overall survival with both regorafenib and best 
supportive care.  With the most optimistic survival for regorafenib (12 months) and pessimistic for best 
supportive care (6 months) the ICER became approximately $98,000 per QALY, and thus considered 
cost-effective. (Table 3) All shorter survival differences between the two arms, would result in ICERs 
above the $100,000 threshold. 
The Monte-Carlo simulation showed that regorafenib therapy was unlikely to be cost-effective, with an 
ICER exceeding $150,000 compared to best supportive care. The ICER was at least $100,000 per QALY in 
99% of simulations and exceeded $200,000 per QALY in 61% of simulations. (Figure 3) If the willingness-
to-pay for QALYs increases dramatically, then regorafenib becomes a more acceptable treatment 
strategy. 
Cost-threshold analysis 
Finally, we conducted a cost threshold analysis to determine the pill cost of regorafenib where it would 
become cost-effective as a second-line therapy for HCC. Supplemental Figure 2 illustrates the ICER vs. 
cost of regorafenib, and it crosses $100,000 per QALY at a cost of $67 per pill. 
DISCUSSION 
 Although regorafenib can provide an additional 2 quality-adjusted life months compared to best 
supportive care for advanced HCC patients who progress on sorafenib, we found it is not a cost-effective 
therapy. Regorafenib consistently had ICERs > $100,000 per QALY in all one-way sensitivity analyses and 
every iteration of cost-effectiveness acceptability curves. In a cost threshold analysis, we found 
regorafenib pill cost would need to be reduced to $67 from its current price of $165 per pill to be cost-
effective. 
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 Two-way sensitivity analysis showed regorafenib could be cost-effective if the survival benefit 
over best supportive care was 6 months or greater. Although this exceeds the survival benefit seen in 
all-comer patients who progress on sorafenib, it may be possible to select a subgroup of patients in 
whom this survival benefit would be observed. It is increasingly clear that HCC is a heterogeneous tumor 
with differences in tumor biology and treatment responsiveness between patients. Similarly, the 
RESORCE Trial focused on patients who progressed on sorafenib, selecting for patients who did not 
respond to multikinase inhibitor therapy, but it is possible regorafenib may have a greater benefit for 
patients who were intolerant to sorafenib or sorafenib-naïve patients (i.e. as first-line therapy). 
Unfortunately, we lack clinically useful biomarkers to predict response to systemic therapy in patients 
with HCC. In a secondary analysis of SHARP data, high s-c-KIT and low hepatocyte growth factor 
concentration at baseline showed a trend toward predicting improved survival among sorafenib-treated 
patients23, however there are not any prognostic biomarkers which have been validated and/or adopted 
for routine clinical use.24-27 Therefore, discovery of clinically useful biomarkers that predict response to 
regorafenib may improve its value as a second line treatment for HCC.  
 Cost-effectiveness incorporates several important factors for deciding therapies including cost, 
clinical effectiveness, and tolerability; however, fails to consider patient preferences and availability of 
other treatment regimens. The importance of pill cost and clinical effectiveness (survival benefit) on 
regorafenib’s cost effectiveness has been discussed above. Although regorafenib can have a high rate of 
AEs, it appears to have minimal detrimental impact on health-related quality of life, as the regorafenib 
and placebo arms had no meaningful differences in quality of life scores.16 These data were derived from 
efficacy trial-based data so it will be important to monitor if regorafenib is equally well tolerated in post-
marketing studies, as has been done for sorafenib in the Global Investigation of Therapeutic Decisions in 
Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON).9 As with all discussions 
regarding cancer treatment, it will be important for providers to discuss and weigh potential pros and 
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cons of second-line treatment with regorafenib. Decisions regarding the role of regorafenib must be 
determined considering each patient’s preferences, goals of care, and quality of life. Importantly, there 
are currently not any effective alternative treatments for patients who progress on sorafenib, thus 
regorafenib is the only option for these patients and fills an important niche in HCC therapy. However, 
there are currently several promising agents, including immunotherapy, that are undergoing evaluation 
in phase II-III studies.28 Given the rapidly changing landscape of HCC therapeutics, cost-effectiveness will 
be increasingly important when considering potentially forthcoming second-line treatment options for 
HCC. 
 Our study has notable strengths and weaknesses. We relied on modeling data from the 
RESORCE Trial, which may not reflect real world practice. Patients in the RESORCE Trial were highly 
selected with excellent functional status and liver function. Real world effectiveness is likely to be worse, 
as has been shown with sorafenib therapy, and thus this would make the ICERs for regorafenib even 
higher so would not change the overall conclusion of our study.8 Patients in RESORCE also had a higher 
burden of extrahepatic versus intrahepatic disease, which has been shown to impact outcomes in HCC.29 
To address this limitation, we performed robust one-way and two-way sensitivity analyses, which 
showed regorafenib was not cost-effective across a wide range of model inputs. This was also confirmed 
in our Monte-Carlo analysis and cost-effectiveness acceptability curves. Finally, our study evaluates 
regorafenib in all-comer patients who progress on sorafenib. Although not cost-effective when 
considered as a group, our analysis cannot account for potential individual differences in treatment 
responsiveness.  
 In summary we have shown that while clinically effective, regorafenib may provide low value as 
a second line therapy for HCC. High costs, coupled with modest clinical effectiveness, are important 
considerations when considering palliative second line therapies for HCC. Significant reduction in 
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regorafenib cost, to better reflect its overall clinical value, or better selection of patients in whom 
survival benefit is maximized would greatly impact regorafenib cost effectiveness.  
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FIGURE LEGENDS 
Figure 1. Markov model structure with health states 
Figure 2. One-way sensitivity analyses showing the ICER as model parameters are varied over their 
ranges. PFS – progression free survival, TTP – time to progression, USD – US dollars 
Figure 3. Cost-effectiveness acceptability curves 
 
ONLINE ONLY 
Supplemental Figure 1A – Model generated progression free survival curve for regorafenib and best 
supportive care 
Supplemental Figure 1B – Model generated overall survival for regorafenib and best supportive care 
Supplemental Figure 2 – Cost-threshold analysis of regorafenib pill cost 
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Table 1: Base case model parameters and one-way sensitivity analysis ranges derived from prior 
literature 
Parameter Value (Range) Source 
Outcomes 
Regorafenib 
Median Overall Survival 10.6 (9.1 to 12.1) months 16 
Median Progression-Free Survival 3.1 (2.4 to 3.8) months 16 
Median Time to Progression 3.2 (2.6 to 3.9) months 16 
Best Supportive Care  
Median Overall Survival 7.8 (6.6 to 9.1) months 16 
Median Progression-Free Survival 1.5 (1.4 to 1.6) months 16 
Median Time to Progression 1.5 (1.4 to 1.6) months 16 
Proportion of Patients with Adverse Events 
Regorafenib 
Hypertension 0.152 (0.116 to 0.188) 16 
Hand-foot skin reaction 0.126 (0.092 to 0.16) 16 
Fatigue 0.091 (0.062 to 0.12) 16 
Diarrhea 0.032 (0.014 to 0.05) 16 
Best Supportive Care 
Hypertension 0.047 (0.017 to 0.077) 16 
Hand-foot skin reaction 0.005 (-0.005 to 0.015) 16 
Fatigue 0.047 (0.017 to 0.077) 16 
Diarrhea 0 (0 to 0) 16 
Weekly Costs 
Regorafenib (per week on drug) $4,156 (3138 to 5174) 18 
Computed Tomography Imaging $234 (177 to 291) 30 
Other care $174 (131 to 216) 31 
   
Hypertension $8.70 ($6.57 to $10.83) 18 
Hand-foot skin reaction $5 ($3.78 to $6.23) 3 
Fatigue $0 ($0 to $0)  
Diarrhea $14.84 ($11.2 to $18.48) 21 
 
Utilities 
HCC Progression-Free 0.76 (0.59 to 0.93) 14, 16, 17 
HCC Progressed 0.76 (0.59 to 0. 93) 14, 16, 17 
Disutilities from Adverse Events 
Hypertension -0.025 (-0.031 to -0.019) 32 
Hand-foot skin reaction -0.116 (-0.144 to -0.088) 33 
Fatigue -0.115 (-0.143 to -0.087) 33 
Diarrhea -0.103 (-0.128 to -0.078) 33 
Duration of Disutilities 
Hypertension 5 (3.8 to 6.2) days 17 
Hand-foot skin reaction 14 (10.6 to 17.4) days 17 
Fatigue 10 (7.6 to 12.5) days 17 
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Diarrhea 5 (3.8 to 6.2) days 17 
Discount Rate 3%  
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Table 2. Cost effectiveness of Regorafenib in the base case scenario. ICER – incremental cost 
effectiveness ratio; QALY – quality adjusted life years 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Costs QALYs ICER 
Best Supportive Care $7,408 0.63  
Regorafenib $47,112 0.81 $224,362 
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Table 3. Incremental cost effectiveness ratios (ICERs) from two-way sensitivity analysis varying median 
overall survival for regorafenib and best supportive care.  
Median Overall Survival  
Best Supportive Care 
6 months 7 months 8 months 9 months 
Regorafenib 
9 months $     191,041 $     301,969 $     753,008 * 
10 months $     145,736 $     199,395 $     321,341 $ 1,380,784 
11 months $     118,888 $     150,696 $     208,009 $     397,501 
12 months $       98,386 $     118,102 $     148,779 $     220,488 
 
*-dominated ,i.e. more expensive and fewer QALYs 
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Figure 1  
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Figure 2  
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Figure 3  
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Supplemental Figure 1A  
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Supplemental Figure 1B  
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Supplemental Figure 2  
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SUPPLEMENTAL MATERIAL 
 
 
Supplemental Table 1. Sensitivity analysis varying HCC progression-associated quality adjusted life year; 
ICER – incremental cost effectiveness ratio; QALY – quality adjusted life years 
QALY for patients with 
HCC progression 
ICER QALY for patients 
without HCC 
progression 
ICER 
0.76 (base case) $224,362  0.76 (base case) $224,362  
0.66 $251,674  0.86 $219,184  
0.56 $286,556  0.96 $214,240  
0.46 $332,664  1 $212,324  
0.36 $396,455  
 
0.26 $490,515  
0.16 $643,091  
0.06 $933,439  
0 $1,280,249  
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